INTRODUCTION
Ocular GvHD following allogeneic stem cell transplantation (aSCT) includes inflammation of the entire lacrimal functional unit and leads to severe damage to the ocular surface. Several forms of ocular GvHD can be differentiated: acute, chronic, late-onset acute and overlap syndromes. The most common form is chronic ocular GvHD, which demonstrates symptoms such as irritation, photophobia, redness, itchiness, foreign body sensation, burning, partial excessive tearing and blurred vision. 1, 2 Until now, there are no specific symptoms, clinical signs or biomarkers available that would allow for a definite diagnosis of ocular GvHD. This disease mimics other immunologically mediated inflammatory diseases such as Sjögren or nonSjögren-associated dry-eye disease and blepharitis, which makes it difficult to definitively diagnose ocular GvHD, particularly in milder cases. 2, 3 Conjunctival probing has been recommended but cannot be performed frequently because of limited excessive tissue and progressive scarring. 4 Clinically, the main affected structures are the lacrimal glands, the conjunctiva with excessive fibrosis and hyperemia (pseudo) membranous conjunctivitis and loss of globlet cells, and the cornea with punctate keratopathy, filamentary keratitis, corneal vascularization and progressively worsening possible perforation. Further observed changes in ocular GvHD include changes in the lid margin with blepharitis and, in particular, alterations in the meibomian glands. 1, 3 Recently, much attention has been paid to meibomian glands, which are sebaceous glands located in the lower and upper tarsus of the eyelid. Each gland consists of multiple acini connected to a long common central duct whose orifice ends at the posterior lid margin. Meibomian glands produce a complex composition of lipids that represent the outer layer of the tear film. Therefore, a functional impairment of meibomian glands (meibomian gland dysfunction) can lead to tear film alterations, increased evaporation and eventually to dry-eye disease. 5, 6 Recently, meibomian gland atrophy and excessive fibrosis around the meibomian glands were observed in ocular GvHD by using in vivo confocal microscopy in a limited number of patients. 5 In addition, the same group described a loss of meibomian gland area in patients suffering from chronic ocular GvHD following aSCT. In this context, meibomian gland loss was described as a typical pathomechanism of ocular GvHD. Despite these findings no information is available concerning the degree and time course of meibomian gland loss in ocular GvHD and whether this is a pathognomonic finding that aids in a definitive diagnosis of ocular GvHD.
This retrospective study was set up to analyze meibomian gland loss following aSCT between healthy controls and patients suffering from different hematologic malignancies prior to aSCT using noninvasive infrared meibography. In addition, meibomian gland area was correlated to clinical disease scores to investigate whether meibomian gland loss could serve as a clinical scoring parameter.
MATERIALS AND METHODS

Data collection
Infrared images of the upper lid meibomian gland of 86 patients after aSCT with ocular GvHD, with GvHD involvement of at least one other organ, of 10 patients after aSCT without ocular GvHD, of 32 patients prior to aSCT and of 30 healthy controls were recorded using the Oculus Keratograph This research adhered to the tenets set forth in the Declaration of Helsinki, and in addition local ethics committee approval was obtained .
Patient characteristics
Patients with acute or chronic lymphocytic or myeloid leukemia, Hodgkin's or non-Hodgkin's lymphoma or myelodysplastic syndrome were included in this retrospective analysis. Regarding conditioning, 27 patients received TBI under different schemes ( Table 1) . The conditioning was myeoablative in 20% of cases, of reduced intensity in 76% of cases and limited to TBI of 2 Gy (mini-conditioning) in 4% of cases. After aSCT all patients were staged for ocular GvHD in accordance with the National Institutes of Health (NIH) consensus criteria 7, 8 on the day of meibography. Further patient characteristics are shown in Tables 1 and 2 .
Meibography
Infrared images of the upper lid meibomian glands were recorded using the Oculus Keratograph 5 M (Oculus) by everting the upper eyelid of the patients.
Meibomian gland grading
All meibography images were evaluated using two different scoring systems: (1) the Meiboscale of Pult (degree 0-4); 9 and (2) semiquantitative analysis using a modified software program.
In the Meiboscale of Pult, degree 0 represents no meibomian gland loss, whereas degree 1 represents a loss of less than 25%, degree 2 a loss Degree of Ocular GvHD in the NIH-classification
Abbreviations: aSCT = allogeneic stem cell transplantation; BM = bone marrow stem cells; FLAMSA = fludarabine/AraC/amsacrine; GIT = gastrointestinal tract; HL = Hodgkin's lymphoma; MDS = myelodysplastic syndrome; Meibogr = meibography; NHL = non-Hodgkin's lymphoma; NIH = National Institutes of Health; PBSCT = peripheral blood stem cells.
between 26 and 50%, degree 3 a loss between 51 and 75% and degree 4 a gland loss of over 75%. For semiautomatic analysis of the uMGA, a method described by Arita et al. was modified using Olympus Soft Imaging Solution's Cell F 3.4. 10 Only images with no disturbing light reflexes and correctly everted upper eyelid were selected for further analysis.
Shading correction and contrast optimization were performed, both of which facilitated recognition of the meibomian glands in contrast to the surrounding tissue. Next, two regions of interest (ROIs) were marked surrounding the entire upper eyelid (outer ROI) and the meibomian glands (inner ROI) to exclude false detection of non-meibomian gland areas at the tarsal margin that demonstrated similar brightness levels. : revised image of normal meibomian glands of the upper eyelid using CellˆF software. This image was revised with different filters and binarization using the software CellˆF. The inner ROI, the green line, represents the area that includes the meibomian glands and the outer dashed red line marks the whole tarsal area of the upper eyelid. The meibomian glands of this healthy control eye are not reduced and the upper meibomian gland area (uMGA) in relation to the whole upper tarsal area represents 48%. (c) revised image of a reduced meibomian gland area. This image was revised with different filters and binarization using the software CellˆF. The inner ROI, the green line, represents the area that includes the meibomian glands and the outer red dashed line marks the whole tarsal area of the upper eyelid. The meibomian glands of this male patient (age 53, 3 years post aSCT due to acute lymphocytic leukemia, chronic ocular GvHD NIH grade 3) are reduced and the uMGA in relation to the whole upper tarsal area represents 13%. Figure 1a shows an infrared image of normal meibomian glands of the upper eyelid of a healthy control eye, which were framed with a green line, the inner ROI, and the entire tarsal plate, which was framed with a red line, the outer ROI. Disturbing light reflexes were excluded from inner and outer ROIs.
The images were then binarized and further filters (erosion and dilatation filters) were applied. The results are shown in Figures 1b and c. Figure 1c shows a representative image with reduced meibomian glands of a patient with ocular GvHD. The uMGA was calculated and set in relation to the total tarsal area of the eyelid. All values of the mentioned areas were counted in pixels. Finally, the percentage of uMGA of the total area of the upper eyelid was evaluated.
Further clinical diagnostic parameters
Best-corrected visual acuity in the logarithm of the minimum angle of resolution, Ocular Surface Disease Index Score (OSDI), Schirmer I test and tear film breakup time (TFBUT) as well as corneal staining were measured in all patients before aSCT and after aSCT, as shown in Table 3 .
The OSDI serves as a standard 12-item questionnaire for patients with dry eye evaluating the severity score for subjective dry-eye symptoms, environmental triggers and their effects on vision-related functioning over the past weeks on a 0-4 scale with a range of 0-100 points.
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Schirmer test I detects insufficiency of the lacrimal glands (Schirmer ⩽ 5 mm at 5 min). 7 The TFBUT was measured by instilling small amounts of fluorescein into the inferior cul-de-sac. To detect the TFBUT, the cornea was observed with the blue light of a cobalt filter, and the time between the last eyelid blink and the appearance of dark areas on the cornea was measured in seconds. 12 For corneal staining, the Oxford grading scheme was applied with a minimum possible grade of 0 to a maximum grade of 5 points. In healthy controls, degree 0 occurs in each case, at around 45%, degree 4 is not present, and only around 4% of controls have degree 3. Degree 4 augments to nearly 30% and degree 3 to 20% in patients with ocular GvHD. In patients prior to aSCT the meiboscale shows an increase in degrees 3 and 4 and a decrease in degree 0, in comparison with healthy controls.
Statistical methods
The mean and standard deviation, median, 25th and 75th percentile and range using the Meiboscale of Pult and semiquantitative analysis of the uMGA were calculated for the following three groups: healthy controls, patients prior to aSCT, and patients with ocular GvHD, and separately for the right and left eye. For best-corrected visual acuity, the Schirmer I test, TFBUT, corneal staining and OSDI, the same statistical values were calculated for patients prior to aSCT and for patients with ocular GvHD. Statistical evaluation was performed using the nonparametric KruskalWallis test to search for significant differences and the Mann-Whitney U-test was performed as a post hoc test. A P-value ⩽ 0.05 was considered statistically significant.
Then, best-corrected visual acuity (logarithm of the minimum angle of resolution), the Schirmer I test, OSDI, TFBUT and corneal staining were set in relation to the uMGA using Spearman's correlation in patients with ocular GvHD, and in case of significant results P-values and positive and negative correlation coefficients were reported.
RESULTS
The uMGA was reliably calculated in all images recorded using the Meiboscale of Pult and the semiquantitative analysis described. Comparison between right and left eyes demonstrated no significant differences. All values for right and left eyes including mean, s.d., median with 25th-75th percentiles and range are presented in Table 3 .
Evaluation of the meibomian gland area using the Meiboscale of Pult indicates that meibomian gland loss is increased both in chronic ocular GvHD and in tumor patients prior to aSCT compared with healthy controls. Figure 2 represents the distribution of the Meiboscale of Pult in each of the following groups: healthy controls, patients prior to aSCT and patients with ocular GvHD. In healthy controls, degree 0 occurred in nearly 55% of right eyes (45% of left eyes), degree 4 was not present in either eye and only around 7% of right eyes (4% of left eyes) of controls showed degree 3. In patients with Figure 3 . Differences in uMGA in healthy controls, in patients prior to aSCT, in patients after aSCT without ocular GvHD and in patients with ocular GvHD (P-values ⩽ 0.05 at a significance level of 5% are considered statistically significant). (a): right eye. Significant differences were detected in the comparison of healthy controls with patients after aSCT with ocular GvHD (P o0.001) and with patients prior to aSCT (P = 0.05), and between patients prior to and after aSCT with ocular GvHD (P = 0.003) and patients after aSCT without ocular GvHD and patients with ocular GvHD (P = 0.01). (b): left eye. Significant differences were detected in the comparison of healthy controls with patients after aSCT with ocular GvHD (P o0.001) and with patients prior to aSCT (P = 0.01), and between patients prior to and after aSCT with ocular GvHD (P = 0.009). ocular GvHD, degree 4 augmented to nearly 30% and degree 3 to 20% in both eyes. In patients prior to aSCT the meiboscale demonstrated an increase in degrees 3 and 4 and a decrease in degree 0 in both eyes compared with healthy controls. The semiquantitative analysis demonstrated significant differences among patients prior to aSCT, patients with ocular GvHD and healthy controls, as shown in Figure 3a for right and Figure 3b for left eyes. The uMGA of healthy controls was significantly higher than that of patients with ocular GvHD (P o 0.001 in both eyes).
In patients prior to aSCT the uMGA was statistically lower in comparison with healthy controls (P = 0.05 in right eyes and 0.01 in left eyes), and significantly higher compared with GvHD patients (P = 0.003 in right eyes and 0.009 in left eyes).
Further, a comparison between patients after aSCT without ocular GvHD and the following groups demonstrated no statistically significant differences: in terms of uMGA in relation to healthy controls (P = 0.29 in right eyes and 0.25 in left eyes) and in relation to patients prior to aSCT (P = 0.60 in right eyes and 0.65 in left eyes). For patients with ocular GvHD and for those after aSCT without ocular GvHD a significant P-value was only detectable for right eyes and not for left eyes (P = 0.01 in right eyes and 0.06 in left eyes).
In addition, we performed a comparison of the two grading methods for all individuals investigated, including healthy controls, patients prior to aSCT and patients with ocular GvHD (Figure 4) . A strong negative correlation between the Meiboscale of Pult and the semiquantitative uMGA with a P-value o 0.001 and a correlation coefficient (r) of − 0.92/ − 0.91 for the right/left eyes were detected.
Statistically significant correlations were found in patients prior to aSCT and with ocular GvHD in the right eyes between uMGA and best-corrected visual acuity (logarithm of the minimum angle of resolution) (P = 0.001, r = − 0.36, in right eyes; P o 0.001, r = − 0.39, in left eyes), between uMGA and OSDI (P = 0.01, r = − 0.29, in right eyes; P = 0.003, r = − 0.28, in left eyes), between uMGA and corneal staining (P = 0.001, r = − 0.37, in right eyes; P = 0.003, r = 0.31, in left eyes) and between uMGA and the Schirmer I test (P = 0.001, r = − 0.37, in right eyes; P = 0.003, r = 0.34, in left eyes). Significant correlation between uMGA and TFBUT was not found (P = 0.65, r = 0.05, in right eyes; P = 0.41, r = 0.09, in left eyes).
uMGA was not correlated with GvHD severity according to the NIH grading scheme (P = 0.061 in right eyes and P = 0.149 in left eyes) ( Figure 5 ).
DISCUSSION
Ban et al. examined meibomian glands with in vivo confocal microscopy in patients with acute or chronic lymphocytic or myeloid leukemia, Hodgkin's or non-Hodgkin's lymphoma or myelodysplastic syndrome with and without ocular GvHD and were able to demonstrate that meibomian glands in ocular GvHD showed severe abnormalities, including atrophic meibomian glands and excessive fibrosis. Also, the meibomian gland area was reported to be reduced in ocular GvHD. 5 These changes were discussed as the result of an inflammatory process, including invasion of inflammatory cells and fibroblast activation, which leads to an accumulation of extracellular matrix. However, from these studies the onset of meibomian gland loss remained unclear as morphological changes in patients prior to aSCT were not examined. 5 This study presents first evidence that morphological changes of meibomian glands cannot entirely be attributed to the pathomechanisms of ocular GvHD, as patients with leukemia or myleodysplastic syndrome prior to aSCT already demonstrate significantly reduced meibomian gland areas.
We observed that especially tumor patients prior to aSCT had a significant reduction in uMGA in comparison with healthy subjects, as well as significantly higher uMGA compared with patients having GvHD after aSCT. These facts imply that meibomian gland loss in GvHD patients may be a multifactorial process that partly also occurs prior to aSCT, possibly because of the underlying diseases with infiltration of the glands by tumor cells and/or related to chemotherapy or irradiation.
Previously, other studies have indicated that factors like irradiation and chemotherapy might also contribute to dry eye after SCT, although chronic GvHD was seen to be the most important cause. [14] [15] [16] Interestingly, no significant differences in uMGA were detected between healthy controls and patients after aSCT without ocular GvHD in the current study.
As we analyzed the data retrospectively, we can only speculate on the final consequence of this finding; however, we hypothesize that Meibomian gland loss prior to aSCT could be a risk factor for the development of ocular GvHD. In addition, we hypothesize that meibomian gland area quantified prior to aSCT could be a predictive factor for estimating the likelihood of the onset of ocular GvHD.
While comparing the uMGA of patients prior to aSCT with that of patients post aSCT without ocular GvHD it becomes obvious that uMGA is larger post aSCT than prior to aSCT. This may implicate a recovery of glands following initial chemotherapy or irradiation. However, on the basis of general ophthalmological understanding on meibomian gland dysfunction, these glands do not recover once destroyed. We propose further follow-up studies in which longitudinal examinations are performed in the same patients over time. This would enable the investigation of the hypothesis stated above and whether those patients prior to aSCT with normal uMGA remain normal without signs of ocular GvHD, whereas those patients prior to aSCT with reduced uMGA would develop ocular GvHD.
Regarding autologous SCT, Ogawa et al. 14 observed that none of the autograft recipients developed dry eye or had a worsening of preexisting dry eye. Our study was limited at that point because only patients receiving an allogeneic SCT were included, but it is likely that meibomian gland loss is also common in autograft recipients prior to and after SCT. This, however, would be the result of mainly chemo-and radiotherapy and could serve as the control group in the following studies.
Our study also indicates that meibomian gland loss after aSCT is not significantly correlated to the current ocular GvHD staging severity score in the NIH consensus criteria. There was only a slightly decreasing trend in uMGA in the eyes that were more affected by ocular GvHD. The latter observation may point to a significant correlation between uMGA possibly seen in further studies when higher numbers of patients with ocular GvHD are included. Presumably, the meibomian gland loss rapidly progresses in ocular GvHD, especially in more severely affected eyes. The objective classification system of the percentage of uMGA is strongly correlated to the subjective scoring system of Pult that is used in routine clinical practice. Arita et al. 10 detected a similar correlation between subjective grading and objective measurements of the meibomian gland area. It can therefore be assumed that a subjective meibomian gland score is sufficient to detect meibomian gland areas in clinical practice. Nevertheless, for an exact examination of the meibomian gland area-for example, in clinical studies-an objective scoring system that can detect more accurately the percentage meibomian gland area seems to be preferable.
Further follow-up studies need to be conducted with higher numbers of patients to underpin these results, to investigate the mechanisms of meibomian gland loss and to identify high-risk from low-risk patients and procedures.
On the basis of our findings we propose that meibomian gland loss in ocular GvHD is a complex process in which the underlying disease, chemotherapy and irradiation may lead to tissue damage and induction of first alterations of the meibomian gland. This prestressed tissue may then form targets for autoimmunological reactions during ocular GvHD through immune cells derived from aSCT.
Overall, based on our results and the correlation of uMGA with visual acuity, corneal staining and the Schirmer I test, we suggest the use of noninvasive infrared meibography as a method for preaSCT examination and post-aSCT follow-up. This could enable early identification of the onset of ocular damage following aSCT. Regarding treatment, we further propose immediate treatment of symptoms of dry eye related to ocular GvHD as the loss of meibomian glands do not necessarily correlate with the severity of symptoms. At present, we perform longitudinal follow-up studies investigating our hypothesis that loss of meibomian glands is a risk factor for the development of ocular GvHD and could serve as a predictor.
